Effective Targeting of Liposomes to Liver and Hepatocytes In Vivo by Incorporation of a Plasmodium Amino Acid Sequence

Longmuir, Kenneth J.; Robertson, Richard T.; Haynes, Sherry M.; Baratta, Janie; Waring, Alan J.

doi:10.1007/s11095-006-9609-x

Cited by 71 publications

(63 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Then, 3 µl of plasma was diluted to 1.0 ml with PBS, and the 488 Dylight and the Bodipy-TRX emission spectra recorded digitally using a Varian Eclipse spectrofluorometer. The rate of clearance of the long-circulating liposomes is known from our previous work (Longmuir et al 2006Robertson et al 2008), and this slow rate of blood clearance (approximately 5 %/h) of red-labeled liposomes was used as a reference against which the measurements of the green Dylight 488-labeled lectin were compared.…”

Section: Methodsmentioning

confidence: 99%

“…2m. When measured as the ratio of green fluorescence (indicating the Dylight 488-labeled lectin) to the red fluorescence (indicating the Bodipy-labeled control liposomes, which are known to be cleared very slowly from circulating blood, Longmuir et al 2006Longmuir et al , 2009, the serum levels of green fluorescence appear to have a half-life of about 15 s, and most is removed by 2 min after injection into the jugular vein.…”

Section: Influence Of Injection Parametersmentioning

confidence: 99%

See 1 more Smart Citation

Use of labeled tomato lectin for imaging vasculature structures

Robertson

Levine

Haynes

et al. 2014

Histochem Cell Biol

Self Cite

166

118

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Section: Influence Of Injection Parametersmentioning

confidence: 99%

Use of labeled tomato lectin for imaging vasculature structures

Robertson

Levine

Haynes

et al. 2014

Histochem Cell Biol

Self Cite

166

118

View full text Add to dashboard Cite

“…ref. (Longmuir et al, 2006)), or an antibody (Spragg et al, 1997), or aptamer (Farokhzad et al, 2006). Passive targeting relies on a specific physiological parameter to act as a filter.…”

Section: Systemic Delivery For Local Therapymentioning

confidence: 99%

Microparticles and nanoparticles for drug delivery

Kohane

2006

Biotech & Bioengineering

448

283

View full text Add to dashboard Cite

Particulate drug delivery systems have become important in experimental pharmaceutics and clinical medicine. The distinction is often made between micro-and nanoparticles, being particles with dimensions best described in micrometers and nanometers respectively. That size difference entails real differences at many levels, from formulation to in vivo usage. Here I will discuss those differences and provide examples of applications, for local and systemic drug delivery. I will outline a number of challenges of interest in particulate drug delivery.

show abstract

“…We recently reported that a 19-amino-acid peptide from the N-terminal region of the circumsporozoite protein of Plasmodium berghei could successfully target systemically administered liposomes to mouse liver (Longmuir et al 2006), with >80% of the liposomal material delivered to hepatocytes. However, it was apparent that considerable research and development would 208 S. M. HAYNES ET AL.…”

Section: Introductionmentioning

confidence: 99%

Liposomal Polyethyleneglycol and Polyethyleneglycol-Peptide Combinations for Active Targeting to LiverIn Vivo

et al. 2008

Self Cite

View full text Add to dashboard Cite

This report describes the development and evaluation of a range of polyethyleneglycol and polyethyleneglycol-peptide liposome formulations that effectively target liver in vivo. A 19-aminoacid sequence from the N-terminal region of the circumsporozoite protein of Plasmodium berghei was attached to the distal end of di22:1-aminopropane-polyethyleneglycol 3400 , and incorporated into liposomes containing di22:1-phosphatidylcholine and di22:1-phosphatidylethanolamine-polyethyleneglycol 5000 . By systematically varying the mole fractions of both the lipid-polyethyleneglycol and the lipid-polyethyleneglycol-peptide conjugates, and screening for serum-induced aggregation in vitro, a serum-stable range of formulations was established. These stable formulations were tested for binding to Hepa 1-6 liver cells in culture, and from these results three formulations were prepared for intravenous administration in mice. All three formulations exhibited effective liposome targeting to the liver, with approximately 80% of the total injected dose recovered in the liver within 15 min. Uptake by liver cells was more than 600-fold higher than uptake by those in the heart, and more than 200-fold higher than uptake by lung or kidney cells. Effective targeting to liver in vivo was successful after repeated (up to three) administrations to the host at 14-day intervals. All formulations prepared for in vivo administration were stable in the presence of serum, as measured by complete retention of entrapped calcein dye. The formulation with the lowest mole fractions of peptide and polyethyleneglycol was the most cost-effective in terms of encapsulation efficiency and minimal use of peptide and polymer com-

show abstract

Effective Targeting of Liposomes to Liver and Hepatocytes In Vivo by Incorporation of a Plasmodium Amino Acid Sequence

Abstract: Incorporation of amino acid sequences that recognize glycosaminoglycans is an effective strategy for the development of targeted drug delivery systems.

Cited by 71 publications

References 42 publications

Use of labeled tomato lectin for imaging vasculature structures

Use of labeled tomato lectin for imaging vasculature structures

Microparticles and nanoparticles for drug delivery

Liposomal Polyethyleneglycol and Polyethyleneglycol-Peptide Combinations for Active Targeting to LiverIn Vivo

Contact Info

Product

Resources

About